Results 211 to 220 of about 101,852 (311)

Association Between p-STAT3/STAT3 Expression and Knosp Grading in Growth Hormone Pituitary Tumors. [PDF]

Neurosurgery
Jiang X, Ye Q, Huang Q, Zou S, Wang C, Mao J, Pan J.   +6 more
europepmc   +1 more source

PITUITARY TUMOR [PDF]

Southern Medical Journal, 1909
openaire   +1 more source

Case Report of IgG4‐Related Autoimmune Pancreatitis

Clinical Case Reports, Volume 14, Issue 4, April 2026.
ABSTRACT This case presents a clear diagnosis with a complete chain of clinical evidence. Long‐term follow‐up revealed that, despite excellent disease control, the condition relapsed more than 6 months after discontinuation of glucocorticoids, with a tendency toward further progression.
Rui Yu, Shiyu Zhang, Yanping Zhao, Jingdong Xiao, Chuijie Wang, Yufeng Li, Ziting Mo, Xihan Zhu   +7 more
wiley   +1 more source

Treatment of canine and feline hyperadrenocorticism: trilostane and the alternatives [PDF]

Bertoy EH, Clemente M, Daley CA, Duesberg CA, Feldman EC, Goossens MM, Graves TK, Henry RW, Kenny PJ, Kipperman BS, Lorenz MD, Mariani CL, Melian C, Nelson RW, Scavelli TD, Théon AP, Valentin SY   +16 more
core   +1 more source

A Review of Vagus Nerve Stimulation for Disease: Comprehensive Theory and Evidence for Mechanisms of Action

Comprehensive Physiology, Volume 16, Issue 2, April 2026.
Vagus nerve stimulation (VNS) effects span central and peripheral organ systems through diverse mechanistic pathways. This comprehensive review provides a unified synthesis of these mechanisms across neurological, cardiovascular, immunological, metabolic, and gastrointestinal domains, filling a critical gap and serving as a foundational resource for ...
Yifeng Bu, Alex Liang, Benjamin U. Hoffman, Dawn M. Schiehser, Oliver Case, Alan Simmons, Ruth Klaming, Andres Gottfried‐Blackmore, Ravinder K. Mittal, Christopher Puleo, Hubert Lim, Imanuel Lerman   +11 more
wiley   +1 more source

Correction to: "Validation and Limitations of the PANOMEN-3 Predictive Model for Tumor Recurrence and Progression in Pituitary Tumors".

J Clin Endocrinol Metab
europepmc   +1 more source

Clinical, surgical, and endocrine outcome following treatment of posterior pituitary tumors: a retrospective cohort study. [PDF]

Pituitary
Kremenevski N, Schnell O, Coras R, Buchfelder M, Hore N.   +4 more
europepmc   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, Volume 119, Issue 4, Page 997-1004, April 2026.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Machine learning method based on radiomics help differentiate posterior pituitary tumors from pituitary neuroendocrine tumors and craniopharyngioma. [PDF]

Sci Rep
Liu Y, Zhou Y, Zhou C, Wang Z, Fan Z, Tang K, Chen S.   +6 more
europepmc   +1 more source